Drug intelligence / Profile preview

S-648414

Development stage: Phase 1
Lead developer: Shionogi
Modality: Small Molecules
Administration: Oral

Overview

S-648414 is an orally available small molecule anti-retroviral drug developed by Shionogi for the treatment of HIV infection. It was investigated in Phase 1 clinical trials to evaluate its safety, tolerability, pharmacokinetics, and potential drug-drug and food interactions in healthy adults. The compound was designed as a novel therapeutic option for HIV but development has been discontinued.

Beyond the preview

Go deeper on S-648414.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on S-648414.

Explore the full profile